spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  bosentan 

 HSMN NewsFeed - 1 Apr 2021
United Therapeutics Announces FDA Approval and Launch of Tyvaso(R) for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 23 Oct 2017
United Therapeutics Announces FDA Approval of Third Generation Nebulizer for the Tyvaso(R) Inhalation System
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 6 Sep 2017
Actelion Receives FDA Approval Of TRACLEER(R) (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jun 2017
Johnson & Johnson Announces Completion of Acquisition of Actelion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Jan 2016
Merck Receives FDA Approval of ZEPATIER(TM) (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 7 Feb 2011
FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 19 Jul 2010
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 28 Apr 2010
Abbott Receives FDA Approval for Once-Daily Dosing of Kaletra(R) (lopinavir / ritonavir) for Treatment-Experienced Patients
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 22 Apr 2010
Actelion Pharmaceuticals Announces Commercial Availability of Epoprostenol for Injection for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 20 Nov 2009
FDA Approves Intravenous Formulation Of Pfizer's Revatio(R) (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Oct 2008
Gilead Announces Two-Year Clinical Data for Letairis(R) (ambrisentan) for the Treatment of Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals
 HSMN NewsFeed - 30 Jun 2008
New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 20 Jun 2008
Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
Biopharmaceuticals
 HSMN NewsFeed - 17 Dec 2007
Actelion Provides Update On Bosentan in Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Nov 2007
Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 24 Oct 2007
Encysive Pharmaceuticals Announces Long-Term Study of Sitaxsentan Presented At Chest Meeting
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2007
Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 15 Jun 2007
U.S. Food and Drug Administration Approves Gilead's Letairis(TM) (ambrisentan) 5 mg and 10 mg Tablets for the Once-Daily Treatment of Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jun 2007
Bosentan (Tracleer) Receives EU Approval for Reduction of Number of New Digital Ulcerations in Systemic Sclerosis Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 May 2007
Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 26 Mar 2007
Bosentan -- Tracleer -- Receives Positive EU Opinion for Reduction of New Digital Ulcerations in Systemic Sclerosis Patients
Biopharmaceuticals
 HSMN NewsFeed - 5 Mar 2007
Actelion: Positive Study With Bosentan (Tracleer) in CTEPH
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2006
Successful Study With Tracleer(r) in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 20 Nov 2006
Actelion Announces Definitive Agreement to Acquire U.S.-Based CoTherix, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Sep 2006
Myogen Initiates Open-Label Phase 3 Clinical Trial of Ambrisentan in Patients with Pulmonary Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
Actelion: ATS Presentation Highlights Strong Rationale for a Morbidity/Mortality Study with Bosentan in Idiopathic Pulmonary Fibrosis
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 35

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 35 additional stories matching:
bosentan
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.